Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA
» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, OTCPK:BAYZF, NYSE:BMY, NYSE:SNY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, NYSE:MRK, OTCPK:NVSEF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, NAS:HCM, OTCPK:MAYNF » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, OXGSK.Switzerland, GSK.UK, GSK.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three areas - pharmaceutical, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.

Ratios

vs
industry
vs
history
PE Ratio 85.65
GLAXF's PE Ratio is ranked lower than
88% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. GLAXF: 85.65 )
Ranked among companies with meaningful PE Ratio only.
GLAXF' s PE Ratio Range Over the Past 10 Years
Min: 4.85  Med: 7.89 Max: 4383.9
Current: 85.65
4.85
4383.9
Forward PE Ratio 14.41
GLAXF's Forward PE Ratio is ranked higher than
52% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. GLAXF: 14.41 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 82.08
GLAXF's PE Ratio without NRI is ranked lower than
87% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. GLAXF: 82.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
GLAXF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.88  Med: 7.88 Max: 4551.72
Current: 82.08
4.88
4551.72
Price-to-Owner-Earnings 13.37
GLAXF's Price-to-Owner-Earnings is ranked higher than
82% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. GLAXF: 13.37 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GLAXF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.79  Med: 8.33 Max: 135.54
Current: 13.37
4.79
135.54
PB Ratio 67.70
GLAXF's PB Ratio is ranked lower than
99% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. GLAXF: 67.70 )
Ranked among companies with meaningful PB Ratio only.
GLAXF' s PB Ratio Range Over the Past 10 Years
Min: 2.76  Med: 5.42 Max: 597.22
Current: 67.7
2.76
597.22
PS Ratio 2.60
GLAXF's PS Ratio is ranked higher than
53% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. GLAXF: 2.60 )
Ranked among companies with meaningful PS Ratio only.
GLAXF' s PS Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.43 Max: 3.32
Current: 2.6
1.09
3.32
Price-to-Free-Cash-Flow 18.06
GLAXF's Price-to-Free-Cash-Flow is ranked higher than
57% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. GLAXF: 18.06 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GLAXF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.04  Med: 8.22 Max: 123.16
Current: 18.06
5.04
123.16
Price-to-Operating-Cash-Flow 11.39
GLAXF's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. GLAXF: 11.39 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GLAXF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.87  Med: 6.45 Max: 26.99
Current: 11.39
3.87
26.99
EV-to-EBIT 33.92
GLAXF's EV-to-EBIT is ranked lower than
76% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. GLAXF: 33.92 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.9  Med: 7 Max: 65.3
Current: 33.92
3.9
65.3
EV-to-EBITDA 19.83
GLAXF's EV-to-EBITDA is ranked lower than
62% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. GLAXF: 19.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.4  Med: 6 Max: 32
Current: 19.83
3.4
32
Shiller PE Ratio 12.73
GLAXF's Shiller PE Ratio is ranked higher than
87% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 47.37 vs. GLAXF: 12.73 )
Ranked among companies with meaningful Shiller PE Ratio only.
GLAXF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 5.3  Med: 6.11 Max: 13.44
Current: 12.73
5.3
13.44
Current Ratio 0.88
GLAXF's Current Ratio is ranked lower than
89% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. GLAXF: 0.88 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.24 Max: 1.72
Current: 0.88
0.88
1.72
Quick Ratio 0.61
GLAXF's Quick Ratio is ranked lower than
89% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. GLAXF: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.99 Max: 1.32
Current: 0.61
0.61
1.32
Days Inventory 208.08
GLAXF's Days Inventory is ranked lower than
83% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. GLAXF: 208.08 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 168.66  Med: 194.07 Max: 233.69
Current: 208.08
168.66
233.69
Days Sales Outstanding 78.49
GLAXF's Days Sales Outstanding is ranked lower than
55% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. GLAXF: 78.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.98 Max: 93.9
Current: 78.49
54.62
93.9

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.20
GLAXF's Dividend Yield % is ranked higher than
97% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. GLAXF: 5.20 )
Ranked among companies with meaningful Dividend Yield % only.
GLAXF' s Dividend Yield % Range Over the Past 10 Years
Min: 5.08  Med: 9.09 Max: 11.83
Current: 5.2
5.08
11.83
Dividend Payout Ratio 14.29
GLAXF's Dividend Payout Ratio is ranked lower than
86% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. GLAXF: 14.29 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GLAXF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.68 Max: 4.3
Current: 14.29
0.46
4.3
3-Year Dividend Growth Rate -3.30
GLAXF's 3-Year Dividend Growth Rate is ranked lower than
68% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. GLAXF: -3.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GLAXF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.4 Max: 14.7
Current: -3.3
0
14.7
Forward Dividend Yield % 4.92
GLAXF's Forward Dividend Yield % is ranked higher than
98% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. GLAXF: 4.92 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.60
GLAXF's 5-Year Yield-on-Cost % is ranked higher than
88% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. GLAXF: 5.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GLAXF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 5.47  Med: 9.79 Max: 12.74
Current: 5.6
5.47
12.74
3-Year Average Share Buyback Ratio -0.30
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. GLAXF: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.1 Max: 4.7
Current: -0.3
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.94
GLAXF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
54% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. GLAXF: 1.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GLAXF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.56  Med: 0.66 Max: 1.95
Current: 1.94
0.56
1.95
Price-to-Median-PS-Value 1.82
GLAXF's Price-to-Median-PS-Value is ranked higher than
59% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. GLAXF: 1.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLAXF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.84  Med: 1 Max: 2.11
Current: 1.82
0.84
2.11
Earnings Yield (Greenblatt) % 2.90
GLAXF's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. GLAXF: 2.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLAXF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.5  Med: 14.3 Max: 26
Current: 2.9
1.5
26
Forward Rate of Return (Yacktman) % -7.27
GLAXF's Forward Rate of Return (Yacktman) % is ranked lower than
82% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. GLAXF: -7.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GLAXF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.9  Med: 14.8 Max: 41.4
Current: -7.27
-5.9
41.4

More Statistics

Revenue (TTM) (Mil) $37,533
EPS (TTM) $ 0.24
Beta1.21
Short Percentage of Float0.00%
52-Week Range $18.16 - 22.98
Shares Outstanding (Mil)4,872.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 35,441 36,680 39,807
EPS ($) 1.29 1.32 1.47
EPS without NRI ($) 1.29 1.32 1.47
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.97%
Dividends per Share ($) 1.00 1.00 1.02
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
If You Want Yield, Look to the UK Feb 19 2017 
Flood of News Presents Buying Opportunity Jan 17 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 
Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders Nov 28 2016 
6 Worthy Dividend Stocks Down 10% or More Nov 22 2016 

More From Other Websites
Top Ranked Growth Stocks to Buy for February 23rd Feb 23 2017
Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs Feb 22 2017
Could BP plc and GlaxoSmithKline plc help you retire early? Feb 17 2017
GlaxoSmithKline’s Valuation Compared to Its Peers Feb 16 2017
GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16 Feb 16 2017
3 hot dividend stocks I’d buy in March Feb 16 2017
British Blue Chips Snub Investor Calls to Show CEO Pay Ratio Feb 16 2017
GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16 Feb 15 2017
Gilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet Feb 14 2017
Performance of GlaxoSmithKline’s Pharmaceuticals Segment in 4Q16 Feb 14 2017
4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
GlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake Feb 14 2017
GlaxoSmithKline’s Revenue Trend for 4Q16 Feb 14 2017
Gilead challenges GSK with strong HIV drug data Feb 14 2017
Gilead challenges GSK with strong HIV drug data Feb 14 2017
Gilead challenges GSK with strong HIV drug data Feb 14 2017
PRESS DIGEST- Financial Times - Feb 14 Feb 13 2017
[$$] GSK claims new HIV combination therapy will be 'less harmful' Feb 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK